Denali Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Denali Therapeutics (DNLI).

Price Target Range — 12 Quarters

Analyst Consensus — 19 Analysts

18Buy

1Hold

Consensus RatingBuy# Analysts19Avg. Consensus PT$35Upside to Avg. PT+98.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 25, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$30→$35
Aug 7, 2026	UBS	Michael Yee	PT Raise	Buy	$25→$34
Jul 23, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$35→$36
Jul 16, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$31→$35
Jul 13, 2026	JP Morgan	Jessica Fye	Reinstates	Overweight	$29
May 26, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$40→$35
May 14, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$42→$40
May 11, 2026	BTIG	Thomas Shrader	Maintained	Buy	$39
May 8, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$25→$23
Apr 22, 2026	Leerink Partners	Marc Goodman	PT Cut	Outperform	$40→$35
Apr 7, 2026	Baird	Joel Beatty	PT Raise	Outperform	$32→$34
Mar 26, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$40→$42
Mar 26, 2026	Goldman Sachs	Salveen Richter	PT Raise	Buy	$35→$40
Mar 26, 2026	Stifel	Paul Mattels	PT Raise	Buy	$34→$41
Mar 26, 2026	Baird	Joel Beatty	PT Raise	Outperform	$29→$32
Mar 26, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$32→$42
Mar 25, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$36→$38
Mar 2, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$32→$36
Feb 24, 2026	Wolfe Research	Rudy Li	Initiate	Peer Perform	—
Feb 6, 2026	BTIG	Thomas Shrader	Maintained	Buy	$32

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.

Benzinga Newsdesk

PRO
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.

Benzinga Newsdesk

Denali Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Denali Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PRO
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

PRO
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PRO
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

People Also Watch

People Also Watch

Denali Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Denali Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PROUBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

PROMorgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

PRODeutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PROJP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

PROMorgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

People Also Watch

People Also Watch

PRO
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PRO
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

PRO
Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

PRO
JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

PRO
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35